{{Use dmy dates|date=April 2022}}
{{Lead rewrite|date=April 2021}}
{{Infobox academic | name = Mark Emberton | occupation = Urologist | known_for = Prostate Cancer Research | workplaces = University College London <br /> University College London Hospital }} '''Mark Emberton''' {{postnominals|country=GBR|size=100%|OBE}} is a urologist and prostate cancer research specialist using novel imaging techniques and minimally invasive treatments to improve diagnosis and treatment of prostate cancer.
Emberton is Professor of Interventional oncology at University College London and dean of its Faculty of Medical Sciences.<ref>{{cite web |title=UCL IRIS Institutional Research Information Service |url=https://iris.ucl.ac.uk/iris/browse/profile?upi=MEMBE52}}</ref> and is honorary consultant urological surgeon at University College Hospital.<ref name="NHS UCLH Our Consultants">{{cite web |title=Our Consultants |url=https://www.uclh.nhs.uk/our-services/find-consultant/professor-mark-emberton |website=NHS UCLH}}</ref> He serves as founding pioneer of the charity Prostate Cancer UK.<ref>{{cite web |title=Prostate Cancer Research UK The Pioneers |url=https://prostatecanceruk.org/about-us/the-pioneers}}</ref>
Emberton is author of over 450 peer-reviewed articles on prostate cancer and urology-related topics in scientific journals, including ''The New England Journal of Medicine'', ''The Lancet'' and ''The BMJ''. His work has been cited almost 30,000 times.<ref>{{cite web |title=Google Scholar |url=https://scholar.google.co.uk/citations?user=-nqARLAAAAAJ&hl=en}}</ref>
== Early life and education ==
Emberton was born in Edinburgh. He was educated at St Boniface's Catholic College before graduating from St Mary's Hospital Medical School with a Bachelor of Medicine/Bachelor of Surgery in clinical medicine in 1985. During his time at St. Mary's, he completed an Intercalated BSc in psychology at Bedford College (1983). He gained a Doctor of Medicine degree in 1997 following a period of research at the Clinical Effectiveness Unit at the Royal College of Surgeons of England, where he led the national Prostatectomy Audit.
He was awarded a sub-specialty Fellowship of the Royal Colleges of Surgeons (FRCS Urol.) in 1997.
== Research and career ==
Emberton is professor of interventional oncology at University College London and was appointed dean of its Faculty of Medical Sciences in 2015.<ref>{{cite web |title=UCL News |date=14 May 2015 |url=https://www.ucl.ac.uk/news/2015/may/professor-mark-emberton-appointed-dean-ucl-faculty-medical-sciences}}</ref> He is also a clinical consultant and surgeon at University College Hospital, London, where he diagnoses and treats patients with prostate cancer.<ref name="NHS UCLH Our Consultants" />
Emberton has a track record in taking ideas through the various phases of evaluation with the result of these ideas becoming a part of routine practice. He did this with self-management of lower urinary tract symptoms,<ref>{{cite web |title=Self-management intervention for men with lower urinary tract symptoms |url=https://www.ucl.ac.uk/impact/case-studies/2014/dec/self-management-intervention-men-lower-urinary-tract-symptoms |website=UCL|date=10 December 2014 }}</ref> with magnetic resonance imaging for men at risk of prostate cancer<ref>{{cite news |title=MRI scans to be trialled as test for prostate cancer |url=https://www.theguardian.com/society/2019/jun/09/mri-scans-to-be-trialled-as-test-for-prostate-cancer |work=The Guardian}}</ref> and, most recently, with tissue preserving therapies for prostate cancer.<ref>{{cite journal |title=Has tailored, tissue-selective tumour ablation in men with prostate cancer come of age? |journal=BJU International |year=2018 |doi=10.1111/bju.14088 |last1=Emberton |first1=Mark |volume=121 |issue=5 |pages=676–677 |pmid=29687953 |s2cid=22611696 |doi-access=free }}</ref>
He oversaw the trial of multi-parametric MRI scanning as a first-line investigation for prostate cancer. The approach was approved by The National Institute for Health and Care Excellence (NICE) in May 2019.<ref>{{cite web |title=Prostate cancer: diagnosis and management |url=https://www.nice.org.uk/guidance/ng131/chapter/rationale-and-impact |website=NICE}}</ref>
Emberton is chief investigator in The Medical Research Centre (MRC) and Cancer Research UK-funded ReIMAGINE Prostate Cancer study which is looking at the determinants and consequences of MRI abnormalities in men<ref>{{cite web |title=ReIMAGINE Prostate Cancer Screening |url=https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-using-a-quick-scan-to-spot-prostate-cancer-early-reimagine-prostate-cancer-screening#undefined |website=Cancer Research UK|date=20 January 2020 }}</ref>
Emberton and his team of researchers are exploring the role of focal therapy in men with prostate cancer.<ref>{{cite journal |title=Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence |journal=European Urology|year=2019 |pmid=30904357 |last1=Marconi |first1=L. |last2=Stonier |first2=T. |last3=Tourinho-Barbosa |first3=R. |last4=Moore |first4=C. |last5=Ahmed |first5=H. U. |last6=Cathelineau |first6=X. |last7=Emberton |first7=M. |last8=Sanchez-Salas |first8=R. |last9=Cathcart |first9=P. |volume=76 |issue=1 |pages=27–30 |doi=10.1016/j.eururo.2019.03.007 |s2cid=85497979 |hdl=10044/1/69039 |hdl-access=free }}</ref> The technique minimises damage to surrounding that tends to occur with surgery or radiotherapy. He led the evaluation of vascular targeted photo-therapy though phase I to phase III.
== Honours and awards ==
{{bulleted list |The BMJ Awards 2019: UK Research Paper of the Year for the PRECISION trial into MRI scanning for prostate cancer diagnosis<ref>{{cite journal |title=The BMJ Awards 2019: UK Research Paper of the Year |url=https://www.bmj.com/content/365/bmj.l1866 |journal=BMJ (Clinical Research Ed.)|year=2019 |pmid=31018915 |last1=Wise |first1=J. |volume=365 |article-number=l1866 |doi=10.1136/bmj.l1866 |s2cid=131774459 |url-access=subscription }}</ref>|Golden Telescope BAUS Award 2007 for outstanding urologist within ten years of appointment<ref>{{cite web |title=Medals & Awards |url=https://www.baus.org.uk/professionals/baus_business/medals_awards.aspx |website=BAUS}}</ref>}}
Emberton was elected a Fellow of the Academy of Medical Sciences in 2016.<ref>{{Cite web |date=2016-04-27|title=New Fellows 2016|url=https://acmedsci.ac.uk/more/news/new-fellows-2016|access-date=2026-05-24|website=Academy of Medical Sciences}}</ref> He was appointed Officer of the Order of the British Empire (OBE) in the 2021 Birthday Honours for services to research and prostate cancer.<ref>{{London Gazette|issue=63377|supp=y|page=B11|date=12 June 2021}}</ref>
==References== {{reflist}}
{{authority control}}
{{DEFAULTSORT:Emberton, Mark}} Category:Year of birth missing (living people) Category:Living people Category:Academics of University College London Category:Medical doctors from Edinburgh Category:Officers of the Order of the British Empire Category:British oncologists Category:British urologists Category:Fellows of the Academy of Medical Sciences (United Kingdom)